On this page

Polymyxin B Sulfate and Trimethoprim

Prescription ANDA TE AT Official labelling
Informational index, not medical advice. Content is reproduced from public FDA and NLM data. Always confirm against the manufacturer's current prescribing information. Report adverse events to FDA MedWatch.

Overview

Brand name
Polymyxin B Sulfate and Trimethoprim
Generic name
Polymyxin B Sulfate and Trimethoprim
Dosage form
Solution
Route
Ophthalmic
Marketing category
ANDA · ANDA
Labeler
REMEDYREPACK INC.
Product type
Human Prescription Drug
DEA schedule
Not scheduled
Active ingredients
2
NDC product codes
6
Packages
6
Data completeness
82% of corroborating sources present

Active ingredients

Source: NDC Directory
Active ingredients and strengths as listed in the NDC Directory.
Ingredient Strength RxCUI Monograph
Polymyxin B Sulfate 10000 [USP'U]/mL 204602 View
Trimethoprim Sulfate 1 mg/mL 244967 View

Forms, strengths and routes

Source: NDC Directory
Dosage form
Solution
Route of administration
Ophthalmic
Presentations
12

Pharmacologic classes are listed in the class section below.

Pharmacologic class

Source: NDC Directory
Established pharmacologic classes (EPC), mechanisms of action (MoA), chemical structures (CS) and physiologic effects (PE).
Class Type Browse
Cytochrome P450 2C8 Inhibitors [MoA] MoA All 56 members
Dihydrofolate Reductase Inhibitor Antibacterial [EPC] EPC 8 members — no class page
Dihydrofolate Reductase Inhibitors [MoA] MoA All 25 members
Organic Cation Transporter 2 Inhibitors [MoA] MoA All 32 members
Polymyxin-class Antibacterial [EPC] EPC All 55 members
Polymyxins [CS] CS All 55 members

Regulatory status

Source: Drugs@FDANDC Directory
Application number
064211
Application type
ANDA · Abbreviated New Drug Application
Approval date
April 13, 1998
Sponsor
SANDOZ
Products on application
1
Submissions recorded
11
Products approved under application 064211.
Product Trade name Form Strength Ingredient Status TE Flags
064211-001 TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE SOLUTION/DROPS POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE Prescription AT RS

Therapeutic equivalence

Source: Orange Book
TE code
AT
Reference Listed Drug
No
Reference Standard
Yes

What this rating means: Therapeutically equivalent — bioequivalence demonstrated (topical dermatological products)

Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.

Approval history

Source: Drugs@FDA
Most recent submissions on application 064211.
Type No. Action Status Date Review
Supplement 16 Labeling Approved May 18, 2020 Standard
Supplement 9 Manufacturing (CMC) Approved December 23, 2002 —
Supplement 8 Manufacturing (CMC) Approved October 1, 2002 —
Supplement 7 Labeling Approved June 13, 2002 —
Supplement 6 Manufacturing (CMC) Approved April 19, 2002 —
Supplement 5 Labeling Approved October 5, 2001 —
Supplement 3 Manufacturing (CMC) Approved August 15, 2000 —
Supplement 4 Manufacturing (CMC) Approved April 7, 2000 —
Supplement 1 Labeling Approved November 29, 1999 —
Supplement 2 Manufacturing (CMC) Approved October 26, 1999 —
Original application 1 Approved April 13, 1998 —

Prescribing information

Source: openFDA Drug Labeling

Reproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20260127). This is the manufacturer's labelling text, not a summary and not advice.

HUMAN PRESCRIPTION DRUG · 20260127 HUMAN PRESCRIPTION DRUG · 20220401

Indications and Usage

openFDA Drug Labeling

INDICATIONS AND USAGE Polymyxin B Sulfate and Trimethoprim Ophthalmic Solution is indicated in the treatment of surface ocular bacterial infections, including acute bacterial conjunctivitis, and blepharoconjunctivitis, caused by susceptible strains of the following microorganisms: Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Streptococcus viridans, Haemophilus influenzae and Pseudomonas aeruginosa. * *Efficacy for this organism in this organ system was studied in fewer than 10 infections.

Dosage and Administration

openFDA Drug Labeling

DOSAGE AND ADMINISTRATION In mild to moderate infections, instill one drop in the affected eye(s) every three hours (maximum of 6 doses per day) for a period of 7 to 10 days.

Contraindications

openFDA Drug Labeling

CONTRAINDICATIONS Polymyxin B Sulfate and Trimethoprim Ophthalmic Solution is contraindicated in patients with known hypersensitivity to any of its components.

WARNINGS NOT FOR INJECTION INTO THE EYE. If a hypersensitivity reaction to Polymyxin B Sulfate and Trimethoprim Ophthalmic Solution occurs, discontinue use. Polymyxin B Sulfate and Trimethoprim Ophthalmic Solution is not indicated for the prophylaxis or treatment of ophthalmia neonatorum.

Adverse Reactions

openFDA Drug Labeling

ADVERSE REACTIONS The most frequent adverse reaction to Polymyxin B Sulfate and Trimethoprim Ophthalmic Solution is local irritation consisting of increased redness, burning, stinging, and/or itching. This may occur on instillation, within 48 hours, or at any time with extended use. There are also multiple reports of hypersensitivity reactions consisting of lid edema, itching, increased redness, tearing, and/or circumocular rash. Stevens- Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN) and anaphylaxis have been reported. Photosensitivity has been reported in patients taking oral trimethoprim. To report SUSPECTED ADVERSE REACTIONS, contact Sandoz Inc., at 1-800-525-8747 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Description

openFDA Drug Labeling

DESCRIPTION Polymyxin B Sulfate and Trimethoprim Ophthalmic Solution is a sterile antimicrobial solution for topical ophthalmic use. It has a pH of 4.0 to 6.2 and osmolality of 270 to 310 mOsm/kg. Chemical Names: Trimethoprim sulfate, 2,4-diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine sulfate (2:1), is a white, odorless, crystalline powder with a molecular weight of 678.72 and the following structural formula: Polymyxin B sulfate is the sulfate salt of polymyxin B 1 and B 2 which are produced by the growth of Bacillus polymyxa (Prazmowski) Migula (Fam. Bacillaceae). It has a potency of not less than 6,000 polymyxin B units per mg, calculated on an anhydrous basis. The structural formula are: Contains: Actives: polymyxin B sulfate 10,000 units/mL; trimethoprim sulfate equivalent to trimethoprim 1mg/mL. Preservative: benzalkonium chloride 0.04 mg/mL. Inactives: sodium chloride; sulfuric acid and purified water. May also contain sodium hydroxide for pH adjustment. trimethoprim-chemical polymyxin-chemical polymyxin-text

How Supplied / Storage and Handling

openFDA Drug Labeling

HOW SUPPLIED Polymyxin B Sulfate and Trimethoprim Ophthalmic Solution, USP is a sterile solution. Each mL contains trimethoprim sulfate equivalent to 1 mg trimethoprim and polymyxin B sulfate 10,000 units in NDC: 70518-1735-00 PACKAGING: 10 mL in 1 BOTTLE PLASTIC TYPE 0 Storage: Store at 15° to 25°C (59° to 77°F) and protect from light. Repackaged and Distributed By: Remedy Repack, Inc. 625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762

Adverse event reports

Source: openFDA FAERS
4,875
FAERS reports mentioning this drug
as of 2026-09-25T03:42:24+00:00
A report count is not a risk measure. FAERS accepts voluntary and mandatory reports without establishing causation, and reporting is influenced by how widely a drug is used, how long it has been marketed, and media attention. FDA states that reports “do not prove that the drug caused the event”. Compare rates, not totals.

Attributed to this product's most-reported active ingredient: POLYMYXIN B SULFATE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.

Packaging and NDCs

Source: NDC Directory
Every National Drug Code package associated with this medication. The NDC is the identifier used for dispensing, billing and pharmacovigilance in the United States.
Package NDC Product NDC Labeler Description Marketing start
50090-2925-0 50090-2925 A-S Medication Solutions 10 mL in 1 BOTTLE, PLASTIC (50090-2925-0) March 16, 2017
68071-4103-5 68071-4103 NuCare Pharmaceuticals,Inc. 10 mL in 1 BOX (68071-4103-5) December 22, 2017
68788-6927-1 68788-6927 Preferred Pharmacetucials Inc. 10 mL in 1 BOTTLE, PLASTIC (68788-6927-1) March 30, 2018
63187-834-10 63187-834 Proficient Rx LP 10 mL in 1 BOTTLE, PLASTIC (63187-834-10) December 1, 2018
70518-1735-0 70518-1735 REMEDYREPACK INC. 10 mL in 1 BOTTLE, PLASTIC (70518-1735-0) December 14, 2018
61314-628-10 61314-628 Sandoz Inc 1 BOTTLE, PLASTIC in 1 CARTON (61314-628-10) / 10 mL in 1 BOTTLE, PLASTIC April 16, 1998
50090-2925 50090-2925 A-S Medication Solutions — April 16, 1998
68071-4103 68071-4103 NuCare Pharmaceuticals,Inc. — April 16, 1998
68788-6927 68788-6927 Preferred Pharmacetucials Inc. — March 30, 2018
63187-834 63187-834 Proficient Rx LP — April 16, 1998
70518-1735 70518-1735 REMEDYREPACK INC. — December 14, 2018
61314-628 61314-628 Sandoz Inc — April 16, 1998

Sources for this page

Every dataset that contributed a fact to this page.
Dataset Agency Used for
NDC Directory FDA Identity, ingredients, strengths, forms, routes, labelers, packages
Drugs@FDA FDA Application, sponsor, submissions, review documents, marketing status
Orange Book FDA Therapeutic equivalence codes, reference drug flags, patents, exclusivity
Drug Labeling FDA / NLM Prescribing information reproduced above
FAERS FDA Adverse event report counts

Generated September 25, 2026 · 12 sections on this page.